Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II

Carla G. Monico, Mai Persson, G. Charles Ford, Gill Rumsby, Dawn S. Milliner

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background. Hyperoxaluria may be idiopathic, secondary, or due to primary hyperoxaluria (PH). Hepatic alanine:glyoxylate aminotransferase (AGT) or glyoxylate/hydroxypyruvate reductase (GR/HPR) deficiency causes PHI or PHII, respectively. Hepatic glycolate oxidase (GO) is a candidate enzyme for a third form of inherited hyperoxaluria. Methods. Six children were identified with marked hyperoxaluria, urolithiasis, and normal hepatic AGT (N = 5) and GR/HPR (N = 4). HPR was below normal and GR not measured in one. Of an affected sibling pair, only one underwent biopsy. GO mutation screening was performed, and dietary oxalate (Dietox), enteric oxalate absorption (EOA) measured using [13C2] oxalate, renal clearance (GFR), fractional oxalate excretion (FEox) in the children, and urine oxalate in first- degree relatives (FDR) to understand the etiology of the hyperoxaluria. Results. Mean presenting age was 19.2 months and urine oxalate 1.3 ± 0.5 mmol/1.73 m2/24 h (mean ± SD). Two GO sequence changes (T754C, IVS3 - 49 C>G) were detected which were not linked to the hyperoxaluria. Dietox was 42 ± 31 mg/day. EOA was 9.4 ± 3.6%, compared with 7.6 > 1.2% in age-matched controls (P = 0.33). GFR was 90 ± 19 mL/min/1.73 m2 and FEox 4.2 ± 1.4. Aside from the two brothers, hyperoxaluria was not found in FDR. Conclusions. These patients illustrate a novel form of hyperoxaluria and urolithiasis, without excess Dietox, enteric hyper-absorption, or hepatic AGT, GR/HPR deficiency. Alterations in pathways of oxalate synthesis, in liver or kidney, or in renal tubular oxalate handling are possible explanations. The affected sibling pair suggests an inherited basis.

Original languageEnglish (US)
Pages (from-to)392-400
Number of pages9
JournalKidney International
Volume62
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Primary Hyperoxaluria
Hyperoxaluria
Oxalates
glyoxylate reductase
Hydroxypyruvate Reductase
Liver
Siblings
Urolithiasis
Kidney
Urine

Keywords

  • Alanine:glyoxylate aminotransferase
  • Calcium oxalate urolithiasis
  • Enteric oxalate absorption
  • Kidney stones
  • Stone formation
  • Urolithiasis

ASJC Scopus subject areas

  • Nephrology

Cite this

Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. / Monico, Carla G.; Persson, Mai; Ford, G. Charles; Rumsby, Gill; Milliner, Dawn S.

In: Kidney International, Vol. 62, No. 2, 2002, p. 392-400.

Research output: Contribution to journalArticle

Monico, Carla G. ; Persson, Mai ; Ford, G. Charles ; Rumsby, Gill ; Milliner, Dawn S. / Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. In: Kidney International. 2002 ; Vol. 62, No. 2. pp. 392-400.
@article{4af9e2c46eaf4ebf996f85f11f8452ad,
title = "Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II",
abstract = "Background. Hyperoxaluria may be idiopathic, secondary, or due to primary hyperoxaluria (PH). Hepatic alanine:glyoxylate aminotransferase (AGT) or glyoxylate/hydroxypyruvate reductase (GR/HPR) deficiency causes PHI or PHII, respectively. Hepatic glycolate oxidase (GO) is a candidate enzyme for a third form of inherited hyperoxaluria. Methods. Six children were identified with marked hyperoxaluria, urolithiasis, and normal hepatic AGT (N = 5) and GR/HPR (N = 4). HPR was below normal and GR not measured in one. Of an affected sibling pair, only one underwent biopsy. GO mutation screening was performed, and dietary oxalate (Dietox), enteric oxalate absorption (EOA) measured using [13C2] oxalate, renal clearance (GFR), fractional oxalate excretion (FEox) in the children, and urine oxalate in first- degree relatives (FDR) to understand the etiology of the hyperoxaluria. Results. Mean presenting age was 19.2 months and urine oxalate 1.3 ± 0.5 mmol/1.73 m2/24 h (mean ± SD). Two GO sequence changes (T754C, IVS3 - 49 C>G) were detected which were not linked to the hyperoxaluria. Dietox was 42 ± 31 mg/day. EOA was 9.4 ± 3.6{\%}, compared with 7.6 > 1.2{\%} in age-matched controls (P = 0.33). GFR was 90 ± 19 mL/min/1.73 m2 and FEox 4.2 ± 1.4. Aside from the two brothers, hyperoxaluria was not found in FDR. Conclusions. These patients illustrate a novel form of hyperoxaluria and urolithiasis, without excess Dietox, enteric hyper-absorption, or hepatic AGT, GR/HPR deficiency. Alterations in pathways of oxalate synthesis, in liver or kidney, or in renal tubular oxalate handling are possible explanations. The affected sibling pair suggests an inherited basis.",
keywords = "Alanine:glyoxylate aminotransferase, Calcium oxalate urolithiasis, Enteric oxalate absorption, Kidney stones, Stone formation, Urolithiasis",
author = "Monico, {Carla G.} and Mai Persson and Ford, {G. Charles} and Gill Rumsby and Milliner, {Dawn S.}",
year = "2002",
doi = "10.1046/j.1523-1755.2002.00468.x",
language = "English (US)",
volume = "62",
pages = "392--400",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II

AU - Monico, Carla G.

AU - Persson, Mai

AU - Ford, G. Charles

AU - Rumsby, Gill

AU - Milliner, Dawn S.

PY - 2002

Y1 - 2002

N2 - Background. Hyperoxaluria may be idiopathic, secondary, or due to primary hyperoxaluria (PH). Hepatic alanine:glyoxylate aminotransferase (AGT) or glyoxylate/hydroxypyruvate reductase (GR/HPR) deficiency causes PHI or PHII, respectively. Hepatic glycolate oxidase (GO) is a candidate enzyme for a third form of inherited hyperoxaluria. Methods. Six children were identified with marked hyperoxaluria, urolithiasis, and normal hepatic AGT (N = 5) and GR/HPR (N = 4). HPR was below normal and GR not measured in one. Of an affected sibling pair, only one underwent biopsy. GO mutation screening was performed, and dietary oxalate (Dietox), enteric oxalate absorption (EOA) measured using [13C2] oxalate, renal clearance (GFR), fractional oxalate excretion (FEox) in the children, and urine oxalate in first- degree relatives (FDR) to understand the etiology of the hyperoxaluria. Results. Mean presenting age was 19.2 months and urine oxalate 1.3 ± 0.5 mmol/1.73 m2/24 h (mean ± SD). Two GO sequence changes (T754C, IVS3 - 49 C>G) were detected which were not linked to the hyperoxaluria. Dietox was 42 ± 31 mg/day. EOA was 9.4 ± 3.6%, compared with 7.6 > 1.2% in age-matched controls (P = 0.33). GFR was 90 ± 19 mL/min/1.73 m2 and FEox 4.2 ± 1.4. Aside from the two brothers, hyperoxaluria was not found in FDR. Conclusions. These patients illustrate a novel form of hyperoxaluria and urolithiasis, without excess Dietox, enteric hyper-absorption, or hepatic AGT, GR/HPR deficiency. Alterations in pathways of oxalate synthesis, in liver or kidney, or in renal tubular oxalate handling are possible explanations. The affected sibling pair suggests an inherited basis.

AB - Background. Hyperoxaluria may be idiopathic, secondary, or due to primary hyperoxaluria (PH). Hepatic alanine:glyoxylate aminotransferase (AGT) or glyoxylate/hydroxypyruvate reductase (GR/HPR) deficiency causes PHI or PHII, respectively. Hepatic glycolate oxidase (GO) is a candidate enzyme for a third form of inherited hyperoxaluria. Methods. Six children were identified with marked hyperoxaluria, urolithiasis, and normal hepatic AGT (N = 5) and GR/HPR (N = 4). HPR was below normal and GR not measured in one. Of an affected sibling pair, only one underwent biopsy. GO mutation screening was performed, and dietary oxalate (Dietox), enteric oxalate absorption (EOA) measured using [13C2] oxalate, renal clearance (GFR), fractional oxalate excretion (FEox) in the children, and urine oxalate in first- degree relatives (FDR) to understand the etiology of the hyperoxaluria. Results. Mean presenting age was 19.2 months and urine oxalate 1.3 ± 0.5 mmol/1.73 m2/24 h (mean ± SD). Two GO sequence changes (T754C, IVS3 - 49 C>G) were detected which were not linked to the hyperoxaluria. Dietox was 42 ± 31 mg/day. EOA was 9.4 ± 3.6%, compared with 7.6 > 1.2% in age-matched controls (P = 0.33). GFR was 90 ± 19 mL/min/1.73 m2 and FEox 4.2 ± 1.4. Aside from the two brothers, hyperoxaluria was not found in FDR. Conclusions. These patients illustrate a novel form of hyperoxaluria and urolithiasis, without excess Dietox, enteric hyper-absorption, or hepatic AGT, GR/HPR deficiency. Alterations in pathways of oxalate synthesis, in liver or kidney, or in renal tubular oxalate handling are possible explanations. The affected sibling pair suggests an inherited basis.

KW - Alanine:glyoxylate aminotransferase

KW - Calcium oxalate urolithiasis

KW - Enteric oxalate absorption

KW - Kidney stones

KW - Stone formation

KW - Urolithiasis

UR - http://www.scopus.com/inward/record.url?scp=0035991408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035991408&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.2002.00468.x

DO - 10.1046/j.1523-1755.2002.00468.x

M3 - Article

C2 - 12110000

AN - SCOPUS:0035991408

VL - 62

SP - 392

EP - 400

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -